| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ce7c542a5a6dc02c10fc2e0a619c4186 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-188
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2730-10152
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-10152
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0278
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-10122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2999-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2730-10122 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0275
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-566 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2013-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ea7a3ed9cff9c3a95bb4410a5c059fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_953861913f2a6a2916b7fec84636c190 |
| publicationDate |
2015-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2917230-A1 |
| titleOfInvention |
Development of hbv- and/or hdv-susceptible cells, cell lines and non-human animals |
| abstract |
The present invention relates to a novel Hepatitis B virus (HBV) and/or Hepatitis D virus (HDV) receptor and its use for the development of cells, cell lines and non-human animals that are susceptible to HBV and/or HDV infection and can be used for immunological studies and/or for the screening of drugs, post-entry restriction factors and host dependency factors. It further relates to the use of the receptor for the identification of compounds useful in the treatment of HBV and/or HDV infection. |
| priorityDate |
2012-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |